556 related articles for article (PubMed ID: 30184433)
1. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial impairment induced by poly(ADP-ribose) polymerase-1 activation in cortical neurons after oxygen and glucose deprivation.
Tanaka S; Takehashi M; Iida S; Kitajima T; Kamanaka Y; Stedeford T; Banasik M; Ueda K
J Neurochem; 2005 Oct; 95(1):179-90. PubMed ID: 16181422
[TBL] [Abstract][Full Text] [Related]
4. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
5. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
6. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
7. Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance.
Gerace E; Scartabelli T; Formentini L; Landucci E; Moroni F; Chiarugi A; Pellegrini-Giampietro DE
Eur J Neurosci; 2012 Jul; 36(1):1993-2005. PubMed ID: 22639866
[TBL] [Abstract][Full Text] [Related]
8. Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress.
Du L; Zhang X; Han YY; Burke NA; Kochanek PM; Watkins SC; Graham SH; Carcillo JA; Szabó C; Clark RS
J Biol Chem; 2003 May; 278(20):18426-33. PubMed ID: 12626504
[TBL] [Abstract][Full Text] [Related]
9. NAD+ as a metabolic link between DNA damage and cell death.
Ying W; Alano CC; Garnier P; Swanson RA
J Neurosci Res; 2005 Jan 1-15; 79(1-2):216-23. PubMed ID: 15562437
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
11. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
[TBL] [Abstract][Full Text] [Related]
12. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
Oh KS; Lee S; Yi KY; Seo HW; Koo HN; Lee BH
J Pharmacol Exp Ther; 2009 Jan; 328(1):10-8. PubMed ID: 18836068
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
14. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system.
Halmosi R; Berente Z; Osz E; Toth K; Literati-Nagy P; Sumegi B
Mol Pharmacol; 2001 Jun; 59(6):1497-505. PubMed ID: 11353811
[TBL] [Abstract][Full Text] [Related]
15. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
[TBL] [Abstract][Full Text] [Related]
16. Insights into the functional aspects of poly(ADP-ribose) polymerase-1 (PARP-1) in mitochondrial homeostasis in Dictyostelium discoideum.
Kadam A; Jubin T; Roychowdhury R; Garg A; Parmar N; Palit SP; Begum R
Biol Cell; 2020 Aug; 112(8):222-237. PubMed ID: 32324907
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase-1 protects neurons against apoptosis induced by oxidative stress.
Diaz-Hernandez JI; Moncada S; Bolaños JP; Almeida A
Cell Death Differ; 2007 Jun; 14(6):1211-21. PubMed ID: 17347665
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
[TBL] [Abstract][Full Text] [Related]
19. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
